Internal shunt and method for treating glaucoma

Information

  • Patent Grant
  • 8444588
  • Patent Number
    8,444,588
  • Date Filed
    Tuesday, February 23, 2010
    14 years ago
  • Date Issued
    Tuesday, May 21, 2013
    11 years ago
Abstract
A surgical technique and device wherein an indwelling tube is placed in the eye of a patient having glaucoma. The tube diverts aqueous humor from the anterior chamber to the suprachoroidal space from which it is removed by blood flowing in the choroidal and uveal tissues. This decreases the intraocular pressure.
Description
FIELD OF THE INVENTION

This invention pertains to a surgical treatment for glaucoma and, more particularly, to a new method and apparatus for surgically alleviating the intraocular pressure causing the glaucoma condition.


BACKGROUND

Glaucoma is an eye condition in which the hydrostatic pressure within the eye is abnormally high, thereby resulting in damage to the optic nerve. There are many treatments for the glaucoma condition that involve lowering the intraocular pressure, either by means of medication or surgery.


Medicinal treatments either decrease the rate at which aqueous humor is pumped into the eye or improve the outflow of aqueous humor from the eye.


There are three primary surgical methods for treating glaucoma. Presently, none of them are a complete answer to the problem:

    • a) Cyclodestructive procedures damage the ciliary body of the eye and decrease the rate of aqueous humor production. The main problem is the extremely fine dividing line between too little and too much treatment. This treatment often does not work, or it works too well. When the surgery works too well, a hypotonous eye may develop in which the pressure is too low for normal ocular function and health.
    • b) Laser therapy of the trabecular meshwork is used to decrease the resistance of outflow of aqueous humor into the Canal of Schlemm. The main problem with this procedure is that it only provides relief for about five years. Re-treatment is often unsuccessful because it may cause too much scarring of the outflow channels. Thus, this procedure can do more harm than good.
    • c) Shunting of aqueous humor from the anterior chamber through the sclera to outside of the confines of the eye is the most common surgical procedure. Among the shunting procedures, the often-performed trabeculectomy is a type of filtering method. It allows aqueous humor to “filter” out of the eye. A channel is created from the anterior chamber under a scleral flap to the episcleral space. The main problem with this procedure is that the outcome depends on the individual healing properties of the eye in the post-operative period. Trabeculectomy is often much less successful in highly pigmented eyes and eyes with previous surgery, rubeosis, or chronic uveitis. To overcome this problem, several shunts have been devised to carry aqueous humor from the anterior chamber to the episcleral space. Scarring often occurs surrounding the exterior end when shunts are used. This renders the outcome unpredictable.


Another problem with these types of surgical procedures is that the globe is left with a transcleral fistula. The fistula renders the eye susceptible to the ingress of organisms and intraocular infection. This condition is known as endophthalmitis and can be devastating to the eye, since the eye is not naturally designed to defend against this type of onslaught.


The invention seeks to provide a surgical treatment and apparatus that will overcome the many problems associated with present-day surgical procedures.


The current invention provides an indwelling shunt that diverts aqueous humor from the anterior chamber to the blood flowing in the choroidal and uveal tissues. This decreases the intraocular pressure of the glaucomatous eye. The indwelling shunt maintains the area of exposure of aqueous humor with the uvea by physically preventing scarring of the surrounding tissues. The method utilizes the normally occurring 25 mm Hg driving force of the protein colloid osmotic pressure of the blood to maximize the flow of aqueous humor out of the eye (Yablonski, M. E., J of Glaucoma, February 2003, 12(1):90-92).


One of the many problems that this inventive procedure overcomes is the normally low outflow of aqueous humor into the uveal blood caused by the normally low hydraulic permeability between the aqueous humor of the anterior chamber and the uveal blood vessels (Yablonski, ibid.). The internal tube shunt of this invention, however, greatly increases the hydraulic permeability between the aqueous humor and the uveal blood vessels, thus greatly increasing the magnitude of the outflow via this route.


The present invention overcomes the two main objections of most of the current surgical approaches: (a) it requires no permanent transcleral route for the egress of aqueous humor from the eye, and (b) the success of the procedure is not as dependent on the individual healing properties of the eye as it is in other procedures. Therefore, the inventive technique not only works in younger eyes, but it also works in eyes of darkly pigmented individuals, and eyes of patients who have had previous surgery. In addition, the inventive procedure leaves no transcleral route in the eye, thus decreasing the susceptibility to endophthalmitis.


In an article by Stegmann (1990), a procedure is described wherein a non-penetrating deep sclerectomy is performed. The procedure was called “viscocanalostomy” because a viscoelastic substance was injected into the cut ends of the canal of Schlemm after the canal was exposed. Like the present technique, Stegmann first created a thin scleral flap, then created a deep sclerectomy by removing the deep sclera, leaving only a thin layer of sclera of 50 to 100 microns in thickness overlying the choroidal tissue beneath.


It should be observed that Stegmann sutured the overlying scleral flap very tightly, thereby eliminating a final transcleral route for aqueous humor drainage. This implied that the intended mechanism for aqueous humor egress was an intraocular shunt. The mechanism of action of the procedure was proposed by Stegmann to be the access of aqueous humor to the newly dilated canal of Schlemm, from which it flowed from the eye by the usual outflow routes. However, if this were the case, the outflow facility of the eyes should be increased, as measured by tonography. No studies have shown an increase in outflow facility after the viscocanalostomy is performed, despite a marked decrease in intraocular pressure.


Another related technique to that of the current invention is the procedure that sutures a collagen implant beneath the scleral flap into the bed of the deep sclerectomy (M. E. Karlen, E. Sanchez, C. C. Schnyder, M. Sickenberg, and A. Mermoud, Deep sclerectomy with collagen implant: medium term results, Br J Ophthalmol, January 1999, 83(1):6-11). The method provides a non-penetrating deep sclerectomy wherein a collagen implant is placed between the overlying scleral flap and the underlying suprachoroidal space. No dilation of the canal of Schlemm is performed. No flow of aqueous humor into the uveal blood is suggested, and only two scleral flap sutures are used, which renders the scleral flap permeable to transcleral flow and creates a transcleral fistula.


In U.S. Pat. No. 6,383,219, issued on May 7, 2002 to Telandro et al., a related non-penetrating deep sclerectomy is illustrated. The method uses an implant made of a cross-linked hydraluronic acid material, which is shaped like a polyhedron having at least five faces. The material is placed between the overlying scleral flap and the underlying suprachoroidal scleral bed. Unlike the current inventive method, this procedure does not propose that the aqueous humor flows mainly into the adjacent uveal blood in response to its protein colloid osmotic pressure. The use of only two sutures in the overlying scleral flap renders this flap permeable to transcleral flow, creating a transcleral fistula.


The stated mechanism for relief in Telandro et al. is the high water content that acts like a wick, i.e., it transports the ocular fluids by capillary action. No mention is made of flow of aqueous humor into the uveal blood, and it is implied that the final destination of the flow of aqueous humor is across the overlying scleral flap into the episcleral space. This method is similar to a conventional trabeculectomy and other filtering procedures.


Some internal shunts have previously been proposed. In U.S. Pat. No. 6,450,984, issued to Lynch and Brown on Sep. 17, 2002, a shunt is illustrated that shunts fluid from the anterior chamber. The shunt is placed under a scleral flap and into the open ends of the canal of Schlemm. This method requires normal drainage of aqueous humor from the canal of Schlemm into the episcleral veins. Since in open angle glaucoma, which is the most common type of glaucoma, flow through the canal of Schlemm is impaired, this technique appears flawed. To the best of knowledge and belief, no reports exist in the literature depicting the successful implementation of this technique.


In U.S. Pat. No. 5,601,094, issued on Feb. 11, 1997 to Reiss, a shunt is described which causes flow of aqueous humor from the anterior chamber to the suprachoroidal space. Unlike the present invention, however, the shunt is exteriorized before it enters the suprachoroidal space. This renders the eye susceptible to endopthalmitis. To the best of knowledge and belief, there have been no successful reports for this technique in the literature.


In U.S. Pat. No. 4,521,210, issued on Jun. 4, 1985 to Wong, a shunt is illustrated that extends from the anterior chamber to the suprachoroidal space. The shunt is designed to create a permanent cyclodialysis cleft and shunt aqueous fluid to the suprachoroidal space from the anterior chamber. The suprachoroidal space is surgically entered and the ciliary body disinserted from the scleral spur. To the best of knowledge and belief, there have not been any reports in the literature of the success of this technique.


SUMMARY

In accordance with the present invention, a surgical technique and apparatus are illustrated for alleviating the glaucoma condition. The current invention provides an indwelling shunt that diverts aqueous humor from the anterior chamber to the blood flowing in the choroidal and uveal tissues. This decreases the intra-ocular pressure. The indwelling shunt maintains the area of exposure of aqueous humor with the uvea by physically preventing scarring of the surrounding tissues. The method utilizes the 25 mm Hg driving force of the protein colloidal osmotic pressure of the blood to maximize the flow.


One method illustrated in FIGS. 1, 3, and 4 comprises the initial step of folding back a one-third scleral thickness scleral flap hinged at the peripheral cornea. A small cavity is generated, extending into the peripheral cornea, by the removal of deep scleral tissue (known as a deep sclerectomy), leaving a very thin, approximately 50 micron in thickness scleral bed (FIG. 4) over the underlying choroid. The suprachoroidal space is entered at the lateral edges of the scleral bed by cutting directly or at a laterally slanted angle. The shunt, which can comprise a precut tube with polished edges, is placed one end permanently into the suprachoroidal space and the other in the scleral lake and is sutured into the overlying sclera. The precut tube can be delivered with a suture in place for ease of deployment. Other examples of structures that can function as a shunt in addition to a hollow tube include a solid section of material grooved to carry aqueous humor, or a structure of open cell foam or other porous material, and similar structures in each case made from biologically compatible materials.


After suturing, one end of the tube is in the suprachoroidal space and the other is in the scleral lake created by the deep sclerectomy. Then a trabeculectomy specimen is created, plus a peripheral iridectomy, as in a standard trabeculectomy. The scleral flap is turned back to its normal position resting on the deep scleral shelf and is sutured to the adjacent sclera with six to ten interrupted sutures to yield a tight closure. The shunt can be fabricated from silicone or other biocompatible materials. One or two such tubes can be placed on each lateral side of the deep sclerectomy. These tubes not only shunt aqueous humor from the scleral lake into the suprachoroidal space, they also help maintain the volume of the scleral lake by acting as a physical barrier between the overlying scleral flap and the underlying scleral bed.


In another version of this procedure (FIG. 2), the scleral lake is smaller and is separated from the anterior chamber by an approximately 3 mm wide layer of full thickness sclera. A tunnel is created with a 23 gauge needle and one end of the tube is inserted through the tunnel into the anterior chamber. The other end of the tube is placed through an incision, at the posterior edge of the scleral bed, into the posterior suprachoroidal space where it is sutured to the overlying sclera. Then the scleral flap is tightly sutured back into place. Other examples of structures that can function as a shunt in addition to a hollow tube include a solid section of material grooved to carry aqueous humor, or a structure of open cell foam or other porous material, and similar structures in each case made from biologically compatible materials.


It is an object of this invention to provide an improved surgical technique and apparatus for treating glaucoma.


It is another object of the present invention to provide both a surgical method and an apparatus that utilizes the uveal blood vessels to drain aqueous humor from the anterior chamber of the eye to decrease intra-ocular pressure in the treatment of glaucoma.





BRIEF DESCRIPTION OF THE DRAWINGS

A complete understanding of the present invention may be obtained by reference to the accompanying drawings, when considered in conjunction with the subsequent detailed description, in which:



FIG. 1 illustrates a top, three-dimensional, perspective, enlarged view of a portion of the eye, shown in partial cut-away;



FIG. 2 depicts a top, three-dimensional perspective view of the second type of internal tube shunt procedure, enlarged view of the portion of the eye, shown in partial cutaway;



FIG. 3 shows a top view of the portion of the eye illustrated in FIG. 1; and



FIG. 4 illustrates a sectional view of the portion of the eye depicted in FIGS. 1 and 3.





For purposes of brevity and clarity, like components and elements of the apparatus of this invention will bear the same designations or numbering throughout the FIGURES.


DETAILED DESCRIPTION

Generally speaking, a surgical technique and apparatus is described wherein an indwelling shunt is placed in the eye of patients having glaucoma. The shunt diverts aqueous humor from the anterior chamber to the suprachoroidal space from which it is removed by the blood flowing in the choroidal and uveal tissues. This decreases the intra-ocular pressure. The indwelling shunt maintains the area of exposure of aqueous humor with the uvea by physically preventing scarring of the surrounding tissues. The method utilizes the 25 mm Hg driving force of the protein colloidal osmotic pressure of the blood to drive aqueous humor into the blood.


In FIGS. 1 through 4, a portion of an eye is shown being surgically prepared with a hollow tube (indwelling shunt) 1 for the treatment of glaucoma. The hollow tube 1 has an interior open space 2 in which fluid (not shown) is transferred. The tube 1 diverts aqueous humor from the scleral lake 8 (FIG. 4) to the suprachoroidal space 12, as best observed with reference to FIGS. 1 and 3. This shunting of the aqueous humor decreases the intra-ocular pressure. The indwelling shunt 1 maintains the area of exposure of aqueous humor with the uvea by physically preventing scarring of the surrounding tissues. The method utilizes the 25 mm Hg driving force of the protein colloidal osmotic pressure of the blood of the uveal blood vessels 14 to maximize the flow (Yablonski, ibid.).


The method comprises the initial step of folding back the scleral flap 4 of the eye (FIG. 1). A small cavity, the deep scleral lake 8, is generated by the removal of tissue in the sclera 7. The suprachoroidal space 12, a normally occurring potential space, is entered by cutting directly, or at a slanted angle through the scleral bed 9. The shunt 1, which can comprise a precut tube with polished edges, is then inserted into the suprachoroidal space 12 and sutured by sutures 15 to the overlying sclera 7 therein, as best seen in FIGS. 1 and 2. The precut tube 1 can also contain sutures fabricated in place for ease of deployment.


After suturing the tube 1 in place, a trabeculectomy specimen 5 may be removed, thus creating a direct communication to the anterior chamber 21 (best seen in FIG. 4). A peripheral iridectomy 6 may be created in the iris 11. The scleral flap 4 is then replaced, resting on the deep scleral shelf 3 where it is tightly sutured to the adjacent sclera 7. The shunt 1 can be fabricated from silicone or other biocompatible materials. It can be seen, therefore, that this technique does not create a permanent cyclodialysis cleft and does not disinsert the ciliary body from the scleral spur.


Referring to FIG. 1, the internal tube shunt 1 of the present invention is inserted and sutured between the suprachoroidal space 12 and the deep scleral lake 8 generated by the surgical forming of a scleral flap 4, and a deep sclerectomy starting 4.5 mm from the limbus and extending into the peripheral cornea 10. Since the deep sclerectomy is about 1 mm smaller than the dimensions of the scleral flap 4, a deep scleral ledge 3 approximately 0.5 mm in width is created on the lateral and posterior aspect of the deep scleral lake 8.


Referring now to FIG. 2, the shunt 1 of the present invention is illustrated passing from the anterior chamber 21 through the adjacent sclera 7, through a posterior deep scleral lake 8, and into the posterior suprachoroidal space 12 where it is sutured to the overlying sclera 7. The deep scleral lake 8 is generated by forming a scleral flap 4 and deep sclerectomy similar to that of FIG. 1 but with an anterior end 3 mm posterior to the cornea 10.


Referring now to FIG. 3, the shunt 1 of the present invention is inserted and laterally sutured into the suprachoroidal space 12 on each side of the deep scleral lake 8 generated by forming a scleral flap 4 and a deep sclerectomy, with the scleral flap 4 sutured back into place over the ends of the tube shunts 1. Also shown are the peripheral iridectomy 6 and the trabeculectomy site 5.


Referring to FIG. 4, the shunt of this invention is seen in the deep scleral lake 8 between the overlying scleral flap 4 and the underlying scleral bed 9. Also shown are the trabeculectomy site 5 and the peripheral iridectomy 6.



FIGS. 1, 3, and 4 show one possible incorporation of the invention where aqueous humor gains access to the shunt 1 via a trabeculectomy 5 between the anterior chamber 21 and the deep scleral lake 8 where one end of the tube 1 lies. From the deep scleral lake 8, aqueous humor is shunted via the tube 1 to the suprachoroidal space 12.



FIG. 2 shows another possible incorporation of the invention in which aqueous humor is shunted directly by a tube 1 that passes from the anterior chamber 21 through the sclera 7 between the anterior chamber 21 and the deep sclerectomy space, and into the suprachoroidal space 12 at the posterior aspect of the deep sclerectomy where it is sutured to the overlying sclera 7.


In this version, the deep sclerectomy is smaller than the deep scleral lake 8 shown in FIGS. 1 and 4. Unlike the version in FIGS. 1 and 4 where the deep scleral lake 8 serves as the pool of aqueous humor which flows into the tube 1, in the version of FIG. 2, the deep sclerectomy serves only to allow the surgeon access for insertion of the tube 1 into the anterior chamber 21, anteriorly, and the suprachoroidal space 12, posteriorly. After the tube 1 is in place, the scleral flap 4 is sutured to the adjacent sclera 7 and no permanent deep scleral lake 8 need persist.


Since other modifications and changes varied to fit particular operating requirements and environments will be apparent to those skilled in the art, the invention is not considered limited to the examples chosen for purposes of disclosure and covers all changes and modifications which do not constitute departures from the true spirit and scope of this invention.


Having thus described the invention, what is desired to be protected by Letters Patent is presented in the subsequently appended claims.

Claims
  • 1. A method of treating glaucoma, comprising: providing an elongated tube comprising at least one inflow port, at least one outflow port and an internal fluid passageway communicating between the at least one inflow port and at least one outflow port;creating a tunnel in eye tissue;inserting the tube through the tunnel;positioning the tube entirely within an interior of the eye such that the at least one inflow port of the fluid passageway is positioned in and communicates with the anterior chamber and the at least one outflow port of the fluid passageway communicates with the suprachoroidal space;leaving only the tube inside the eye; anddiverting aqueous humor through the fluid passageway from the anterior chamber toward the suprachoroidal space.
  • 2. A method as in claim 1, wherein implanting the tube entirely within an interior of the eye comprises implanting the tube so that the tube is positioned radially inward of an outer surface of the sclera.
  • 3. A method as in claim 1, wherein implanting the tube entirely within an interior of the eye comprises implanting the tube so that at least one inflow port is positioned in the anterior chamber posterior of an inner surface of the cornea.
  • 4. The method of claim 1, wherein the tube comprises a rounded, outer surface that contacts a portion of the sclera.
  • 5. The method of claim 1, further comprising attaching a retaining structure to an end of the tube.
  • 6. The method of claim 5, wherein the retaining structure comprises a suture attached to a distal end of the shunt.
  • 7. The method of claim 1, further comprising cutting the tube prior to implantation.
  • 8. A method of treating glaucoma, comprising: providing a tube having an internal lumen, a first opening for fluid to flow into the internal lumen, and a second opening for fluid to flow out of the internal lumen;creating a tunnel in eye tissue;inserting the tube through the tunnel;positioning the tube inside an eye so that the first opening is inside the anterior chamber and the second opening communicates with the suprachoroidal space;leaving only the tube inside the eye; andcausing fluid to flow from the anterior chamber into the internal lumen through the first opening and out of the internal lumen toward the suprachoroidal space through the second opening.
  • 9. A method as in claim 8, wherein positioning the tube inside an eye comprises implanting the tube so that the tube is positioned radially inward of an outer surface of the sclera.
  • 10. A method as in claim 8, wherein implanting the tube inside an eye comprises implanting the tube so that the first opening is positioned in the anterior chamber posterior of an inner surface of the cornea.
  • 11. The method of claim 8, wherein the tube comprises a rounded, outer surface that contacts a portion of the sclera.
  • 12. The method of claim 1, wherein the tunnel is created using a needle.
  • 13. The method of claim 1, wherein the outflow port is positioned in the suprachoroidal space.
  • 14. The method of claim 1, wherein the tube is cylindrical.
  • 15. The method of claim 1, wherein aqueous humor flows directly into the suprachoroidal space via the fluid passageway.
  • 16. The method of claim 8, wherein the tunnel is created using a needle.
  • 17. The method of claim 8, wherein the second opening is positioned in the suprachoroidal space.
  • 18. The method of claim 8, wherein the tube is cylindrical.
  • 19. The method of claim 1, wherein aqueous humor flows directly into the suprachoroidal space via the internal lumen.
RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 11/509,327, filed Aug. 23, 2006, entitled “Internal shunt and method for treating glaucoma,” which is a continuation of U.S. patent application Ser. No. 10/429,336, filed May 5, 2003 now abandoned. The subject matter of each of the above-noted applications is incorporated by reference in their entirety by reference thereto.

US Referenced Citations (262)
Number Name Date Kind
3767759 Wichterle Oct 1973 A
3788327 Donowitz Jan 1974 A
3915172 Wichterle Oct 1975 A
4037604 Newkirk Jul 1977 A
4402681 Haas Sep 1983 A
4457757 Molteno Jul 1984 A
4521210 Wong Jun 1985 A
4554918 White Nov 1985 A
4604087 Joseph Aug 1986 A
4634418 Binder Jan 1987 A
4722724 Schocket Feb 1988 A
4750901 Molteno Jun 1988 A
4787885 Binder Nov 1988 A
4826478 Schocket May 1989 A
4846172 Berlin Jul 1989 A
4863457 Lee Sep 1989 A
4886488 White Dec 1989 A
4900300 Lee Feb 1990 A
4946436 Smith Aug 1990 A
4968296 Ritch et al. Nov 1990 A
5041081 Odrich Aug 1991 A
5071408 Ahmed Dec 1991 A
5073163 Lippman Dec 1991 A
5092837 Ritch et al. Mar 1992 A
5127901 Odrich Jul 1992 A
5171213 Price, Jr. Dec 1992 A
5178604 Baerveldt et al. Jan 1993 A
5180362 Worst Jan 1993 A
5300020 L'Esperance, Jr. Apr 1994 A
5338291 Speckman et al. Aug 1994 A
5342370 Simon et al. Aug 1994 A
5346464 Camras Sep 1994 A
5370607 Memmen Dec 1994 A
5372577 Ungerleider Dec 1994 A
5397300 Baerveldt et al. Mar 1995 A
5433701 Rubinstein Jul 1995 A
5443505 Wong et al. Aug 1995 A
5454746 Guegan et al. Oct 1995 A
5476445 Baerveldt et al. Dec 1995 A
5558629 Baerveldt et al. Sep 1996 A
5558630 Fisher Sep 1996 A
5601094 Reiss Feb 1997 A
5626558 Suson May 1997 A
5626559 Solomon May 1997 A
5651782 Simon et al. Jul 1997 A
5676944 Alvarado et al. Oct 1997 A
5702414 Richter et al. Dec 1997 A
5704907 Nordquist et al. Jan 1998 A
5713844 Peyman Feb 1998 A
5741292 Mendius Apr 1998 A
5743868 Brown et al. Apr 1998 A
5752928 de Roulhac et al. May 1998 A
5807302 Wandel Sep 1998 A
5868697 Richter et al. Feb 1999 A
5882327 Jacob Mar 1999 A
5893837 Eagles et al. Apr 1999 A
5968058 Richter et al. Oct 1999 A
6007510 Nigam Dec 1999 A
6007511 Prywes Dec 1999 A
6019786 Thompson Feb 2000 A
6050970 Baerveldt Apr 2000 A
6077299 Adelberg et al. Jun 2000 A
6102045 Nordquist et al. Aug 2000 A
6142969 Nigam Nov 2000 A
6186974 Allan et al. Feb 2001 B1
6203513 Yaron et al. Mar 2001 B1
6221078 Bylsma Apr 2001 B1
6251090 Avery et al. Jun 2001 B1
6261256 Ahmed Jul 2001 B1
6264668 Prywes Jul 2001 B1
6331313 Wong et al. Dec 2001 B1
6375642 Grieshaber et al. Apr 2002 B1
6383219 Telandro et al. May 2002 B1
6450984 Lynch et al. Sep 2002 B1
6464724 Lynch et al. Oct 2002 B1
6468283 Richter et al. Oct 2002 B1
6471666 Odrich Oct 2002 B1
6471777 Kobayashi et al. Oct 2002 B1
6508779 Suson Jan 2003 B1
6510600 Yaron et al. Jan 2003 B2
6524275 Lynch et al. Feb 2003 B1
6533768 Hill Mar 2003 B1
6537568 Olejnik et al. Mar 2003 B2
6544208 Ethier et al. Apr 2003 B2
6544249 Yu et al. Apr 2003 B1
6558342 Yaron et al. May 2003 B1
6589203 Mitrev Jul 2003 B1
6595945 Brown Jul 2003 B2
6626858 Lynch et al. Sep 2003 B2
6638239 Bergheim et al. Oct 2003 B1
6648283 Chase et al. Nov 2003 B2
6666841 Gharib et al. Dec 2003 B2
6676607 de Juan, Jr. et al. Jan 2004 B2
6699210 Williams et al. Mar 2004 B2
6699211 Savage Mar 2004 B2
6719750 Varner et al. Apr 2004 B2
6726664 Yaron et al. Apr 2004 B2
6730056 Ghaem et al. May 2004 B1
6736791 Tu et al. May 2004 B1
6741666 Henry et al. May 2004 B1
6780164 Bergheim et al. Aug 2004 B2
6783544 Lynch et al. Aug 2004 B2
6827699 Lynch Dec 2004 B2
6827700 Lynch et al. Dec 2004 B2
6881197 Nigam Apr 2005 B1
6881198 Brown Apr 2005 B2
6939298 Brown et al. Sep 2005 B2
6955656 Bergheim et al. Oct 2005 B2
6962573 Wilcox Nov 2005 B1
6966888 Cullen et al. Nov 2005 B2
6969384 de Juan, Jr. et al. Nov 2005 B2
6981958 Gharib et al. Jan 2006 B1
6989007 Shadduck Jan 2006 B2
7041077 Shields May 2006 B2
7090681 Weber Aug 2006 B2
7094225 Tu et al. Aug 2006 B2
7135009 Tu Nov 2006 B2
7160264 Lisk, Jr. et al. Jan 2007 B2
7163543 Smedley et al. Jan 2007 B2
7186232 Smedley Mar 2007 B1
7192412 Zhou et al. Mar 2007 B1
7195774 Carvalho et al. Mar 2007 B2
7207965 Simon Apr 2007 B2
7220238 Lynch et al. May 2007 B2
7273475 Tu et al. Sep 2007 B2
7291125 Coroneo Nov 2007 B2
7297130 Bergheim et al. Nov 2007 B2
7331984 Tu et al. Feb 2008 B2
7431710 Tu et al. Oct 2008 B2
7488303 Haffner et al. Feb 2009 B1
7857782 Tu et al. Dec 2010 B2
20020013546 Grieshaber et al. Jan 2002 A1
20020013572 Berlin Jan 2002 A1
20020072673 Yamamoto et al. Jun 2002 A1
20020087111 Ethier et al. Jul 2002 A1
20020111608 Baerveldt Aug 2002 A1
20020128613 Nakayama Sep 2002 A1
20020133168 Smedley et al. Sep 2002 A1
20020143284 Tu et al. Oct 2002 A1
20020177856 Richter et al. Nov 2002 A1
20020193725 Odrich Dec 2002 A1
20030055372 Lynch et al. Mar 2003 A1
20030060752 Bergheim et al. Mar 2003 A1
20030097151 Smedley et al. May 2003 A1
20030097171 Elliott May 2003 A1
20030135149 Cullen Jul 2003 A1
20030181848 Bergheim et al. Sep 2003 A1
20030187384 Bergheim et al. Oct 2003 A1
20030208163 Yaron et al. Nov 2003 A1
20030229303 Haffner et al. Dec 2003 A1
20030236483 Ren Dec 2003 A1
20030236484 Lynch et al. Dec 2003 A1
20040015140 Shields Jan 2004 A1
20040024345 Gharib et al. Feb 2004 A1
20040088048 Richter et al. May 2004 A1
20040092856 Dahan May 2004 A1
20040102729 Haffner et al. May 2004 A1
20040111050 Smedley et al. Jun 2004 A1
20040127843 Tu et al. Jul 2004 A1
20040147870 Burns et al. Jul 2004 A1
20040148022 Eggleston Jul 2004 A1
20040193095 Shadduck Sep 2004 A1
20040193262 Shadduck Sep 2004 A1
20040210181 Vass et al. Oct 2004 A1
20040210185 Tu et al. Oct 2004 A1
20040216749 Tu et al. Nov 2004 A1
20040236343 Taylor et al. Nov 2004 A1
20040249333 Bergheim et al. Dec 2004 A1
20040254517 Quiroz-Mercado et al. Dec 2004 A1
20040254519 Tu et al. Dec 2004 A1
20040254520 Porteous et al. Dec 2004 A1
20040254521 Simon Dec 2004 A1
20040260228 Lynch et al. Dec 2004 A1
20050008673 Snyder et al. Jan 2005 A1
20050049578 Tu et al. Mar 2005 A1
20050090806 Lynch et al. Apr 2005 A1
20050090807 Lynch Apr 2005 A1
20050119601 Lynch et al. Jun 2005 A9
20050119636 Haffner et al. Jun 2005 A1
20050119737 Bene Jun 2005 A1
20050125003 Pinchuk et al. Jun 2005 A1
20050143817 Hunter et al. Jun 2005 A1
20050149080 Hunter et al. Jul 2005 A1
20050175663 Hunter et al. Aug 2005 A1
20050181011 Hunter et al. Aug 2005 A1
20050181977 Hunter et al. Aug 2005 A1
20050182350 Nigam Aug 2005 A1
20050191331 Hunter et al. Sep 2005 A1
20050192527 Gharib et al. Sep 2005 A1
20050197613 Sniegowski et al. Sep 2005 A1
20050209549 Bergheim et al. Sep 2005 A1
20050209550 Bergheim et al. Sep 2005 A1
20050232972 Odrich Oct 2005 A1
20050244462 Farooq Nov 2005 A1
20050250788 Tu et al. Nov 2005 A1
20050267397 Bhalla Dec 2005 A1
20050267398 Protopsaltis et al. Dec 2005 A1
20050271704 Tu et al. Dec 2005 A1
20050273033 Grahn et al. Dec 2005 A1
20050277864 Haffner et al. Dec 2005 A1
20050283108 Savage Dec 2005 A1
20050288617 Yaron et al. Dec 2005 A1
20050288619 Gharib et al. Dec 2005 A1
20060020248 Prescott Jan 2006 A1
20060032507 Tu et al. Feb 2006 A1
20060036207 Koonmen et al. Feb 2006 A1
20060069340 Simon Mar 2006 A1
20060074375 Bergheim et al. Apr 2006 A1
20060084907 Bergheim et al. Apr 2006 A1
20060116626 Smedley et al. Jun 2006 A1
20060155238 Shields Jul 2006 A1
20060173397 Tu et al. Aug 2006 A1
20060195055 Bergheim et al. Aug 2006 A1
20060195056 Bergheim et al. Aug 2006 A1
20060200113 Haffner et al. Sep 2006 A1
20060235367 Takashima et al. Oct 2006 A1
20060241749 Tu et al. Oct 2006 A1
20070010827 Tu et al. Jan 2007 A1
20070088242 Coroneo Apr 2007 A1
20070088432 Solovay et al. Apr 2007 A1
20070106235 Coroneo May 2007 A1
20070106236 Coroneo May 2007 A1
20070112292 Tu et al. May 2007 A1
20070118147 Smedley et al. May 2007 A1
20070191863 De Juan Aug 2007 A1
20070233037 Gifford, III et al. Oct 2007 A1
20070276315 Haffner et al. Nov 2007 A1
20070276316 Haffner et al. Nov 2007 A1
20070282244 Tu et al. Dec 2007 A1
20070282245 Tu et al. Dec 2007 A1
20070293807 Lynch et al. Dec 2007 A1
20080015488 Tu et al. Jan 2008 A1
20080045878 Bergheim et al. Feb 2008 A1
20080195027 Coroneo Aug 2008 A1
20080200860 Tu et al. Aug 2008 A1
20080228127 Burns et al. Sep 2008 A1
20080234624 Bergheim et al. Sep 2008 A2
20090036819 Tu et al. Feb 2009 A1
20090138022 Tu et al. May 2009 A1
20090182421 Silvestrini Jul 2009 A1
20100010416 Juan, Jr. et al. Jan 2010 A1
20100137981 Silvestrini Jun 2010 A1
20100274258 Silvestrini et al. Oct 2010 A1
20100274259 Yaron et al. Oct 2010 A1
20100280317 Silvestrini et al. Nov 2010 A1
20110028883 Juan, Jr. et al. Feb 2011 A1
20110028884 Theodore Coroneo Feb 2011 A1
20110028983 Silvestrini et al. Feb 2011 A1
20110087148 Silvestrini et al. Apr 2011 A1
20110087149 Theodore Coroneo Apr 2011 A1
20110087150 Theodore Coroneo Apr 2011 A1
20110087151 Theodore Coroneo Apr 2011 A1
20110098629 Juan, Jr. et al. Apr 2011 A1
20110105990 Silvestrini May 2011 A1
20110112546 Juan, Jr. et al. May 2011 A1
20110118835 Silvestrini et al. May 2011 A1
20110238075 Clauson et al. Sep 2011 A1
20110306915 De Juan, Jr. et al. Dec 2011 A1
20120016286 Silvestrini Jan 2012 A1
20120022429 Silvestrini Jan 2012 A1
20120035524 Silvestrini Feb 2012 A1
20120035525 Silvestrini Feb 2012 A1
Foreign Referenced Citations (69)
Number Date Country
0 228 185 Jul 1987 EP
1184010 Mar 2002 EP
1310222 May 2003 EP
1473004 Nov 2004 EP
1477146 Nov 2004 EP
1418868 Mar 2008 EP
1977724 Oct 2008 EP
1545655 Dec 2008 EP
2027837 Feb 2009 EP
2101891 Jan 1983 GB
2018289 Aug 1994 RU
2056818 Mar 1996 RU
2074686 Mar 1997 RU
2074687 Mar 1997 RU
2157678 Oct 2000 RU
8900869 Feb 1989 WO
9112046 Aug 1991 WO
9219294 Nov 1992 WO
9409721 May 1994 WO
9409837 May 1994 WO
9413234 Jun 1994 WO
WO 9508310 Mar 1995 WO
9620742 Jul 1996 WO
9636377 Nov 1996 WO
9823237 Jun 1998 WO
9830181 Jul 1998 WO
9926567 Jun 1999 WO
0006223 Feb 2000 WO
0064389 Nov 2000 WO
0064390 Nov 2000 WO
0064391 Nov 2000 WO
0064393 Nov 2000 WO
0064511 Nov 2000 WO
0178631 Oct 2001 WO
0178656 Oct 2001 WO
0197727 Dec 2001 WO
0236052 May 2002 WO
02070045 Sep 2002 WO
02074052 Sep 2002 WO
02080811 Oct 2002 WO
02080829 Oct 2002 WO
02087418 Nov 2002 WO
02087479 Nov 2002 WO
02089699 Nov 2002 WO
02102274 Dec 2002 WO
03015659 Feb 2003 WO
03015667 Feb 2003 WO
WO 03041622 May 2003 WO
03073968 Sep 2003 WO
03099175 Dec 2003 WO
2004014218 Feb 2004 WO
2004026347 Apr 2004 WO
2004043231 May 2004 WO
2004056294 Jul 2004 WO
2004060219 Jul 2004 WO
2004062469 Jul 2004 WO
2004110391 Dec 2004 WO
2005016418 Feb 2005 WO
2005046782 May 2005 WO
2005055873 Jun 2005 WO
2005105197 Nov 2005 WO
2005107664 Nov 2005 WO
2005107845 Nov 2005 WO
2006012421 Feb 2006 WO
2006036715 Apr 2006 WO
2007087061 Aug 2007 WO
2007115259 Oct 2007 WO
2007130393 Nov 2007 WO
2008061043 May 2008 WO
Non-Patent Literature Citations (96)
Entry
Bick MW “Use of tantalum for ocular drainage” Arch Ophthal. 42(4): 373-88 (1949).
Bietti “The present state of the use of plastics in eye surgery” Acta Ophthalmol (Copenh) 33(4):337-70 (1955).
Classen et al. “A histopathologic and immunohistorchemical analysis of the filtration bleb after unsuccessful glaucoma seton implantation” Am. J. Ophthalmol. 122:205-12 (1996).
Cohen et al. “First day post-operative review following uncomplicated phacoemulsification” Eye 12(4):634-6 (1998).
Derwent English abstract for EP 1184010, published Mar. 6, 2002 entitled: “Drainage unit for an eye, consists of a hollow line, a distribution member, and a pressure relief valve which only allows water to leave the eye chamber above a certain pressure,” Accession Nbr. 12409716 [351].
Dinakaran et al. “Is the first post-operative day review necessary following uncomplicated phacoemulsification surgery?” Eye, 14(3A):364-6 (2000).
Einmahl et al. “Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye” Invest Ophthalmol Vis Sci. 43:1533-1539 (2002).
Emi et al. “Hydrostatic pressure of the suprachoroidal space” Invest. Ophthal. Visual Sci. 30(2):233-238 (1989).
Fuchs E. “Detachment of the choroid inadvertently during cataract surgery” [German] von Graefes Arch Ophthalmol, 51:199-224 (1900).
Gills et al. “Action of cyclodialysis utilizing an implant studied by manometry in a human eye” Exp Eye Res 1967; 6:75-78.
Gills JP “Cyclodialysis implants” South Med J. 1967 60(7):692-5.
Gross et al. “Surgical therapy of chronic glaucoma in aphakia and pseudophakia” Ophthalmology, 95:1195-201 (1988).
Heine I. “Cyclodialysis, a new glaucoma operation” [German] Dtsch Med Wochenschr, 31:824-826 (1905).
Hildebrand et al. “Efficacy of anterior chamber decompression in controlling early intraocular pressure spikes after uneventful phacoemulsification” J. Catact Refract Surg., 29:1087-92 (2003).
Howorth D J “Feasibility study for a micromachined glaucoma drainage device” Cranfield University School of industrial and manufacturing science MSc Thesis Academic Year 2001-2002 Sep. 13, 2002.
Hylton et al. “Update on prostaglandin analogs” Curr Opin Ophthalmol, 14:65-9 (2003).
Jordan J. “A Novel Approach to Suprachoroidal Drainage for the Surgical Treatment of Intractable Glaucoma” J. Glaucoma 15:200-205 (2006).
Karlen et al. “Deep sclerectomy with collagen implant: medium term results” Br. J. Ophthalmol, Jan. 1999, 83(1):6-11.
Klemm et al. “Experimental use of space-retaining substances with extended duration: functional and morphological results” Graefes Arch Clin Exp Ophthalmol Sep. 1995; 233(9):592-7.
Kozlov et al. “Nonpenetrating deep sclerectomy with collagen” Eye microsurgery 3:44-46 (1990) [Russion with English translation].
Krejci “Cyclodialysis with hydroxymethyl methacrylate capillary strip (HCS). Animal experiments with a new approach in glaucoma drainage surgery” Ophthalmologica 1972; 164(2):113-21.
Lee et al. “Magnetic resonance imaging of the aqueous flow in eyes implanted with the trabeculo-suprachoroidal glaucoma seton” Invest. Ophthalmol. Vis. Sci. 33:948 (1992).
Losche W. “Proposals for improvement of cyclodialysis” Klin Monatsblatter Augenheilkd Augenarztl Fortbild 121(6):715-6 (1952) [German].
Nesterov AP et al. “Surgical stimulation of the uveoscleral outflow. Experimental studies on enucleated human eyes” Acta Opthalmol (Copenh) June; 57(3):409-17 (1979).
Ozdamar et al. “Suprachoroidal seton implantation in refractory glaucoma: a novel surgical technique” J. Glaucoma Aug. 2003; 12(4):354-9.
Pinnas G. et al. “Cyclodialysis with teflon tube implants” Am J. Ophthalmol 1969 Nove; 68(5):879-883.
Rosenberg et al. “Implants in glaucoma surgery” Chapter 88, The Glaucomas, Ritch et al. Eds. 2nd Ed. Mosby St. Louis 1986; p. 1783-1807.
Row H. “Operation to control glaucoma: preliminary report” Arch. Ophthal 12:325 (1934).
Srinivasan et al. “Microbial contamination of the anterior chamber during phacoemulsification” J. Cataract Refract Surg. 28:2173-6 (2002).
Toris et al. “Aqueous humor dynamics in the aging human eye” Am J. Ophthalmol., 127:407-12 (1999).
Troncosco UM “Cyclodialysis with insertion of metal implant in treatment of glaucoma Preliminary report” Arch. Ophthal. 23:270 (1940).
Yablonski, “Some thoughts on the pressure dependence of uveoscleral flow” Journal of Glaucoma, 12(1):90-92 (2003).
Yablonski, “Trabeculectomy with Internal Tube Shunt: a novel glaucoma surgery” J. Glaucoma 14:91-97 (2005).
Barsky et al. “Evaluation of absorbable gelatin film (Gelfilm) in cyclodialysis clefts” Arch. Ophth. 60(6): 1044-1052,1958.
Brown et al., “Internal Sclerectomy for Glaucoma Filtering Surgery with an Automated Trephine,” Archives of Ophthalmology, 105:133-136 (1987).
Burchfield JC, Kass MA, Wax MB. Primary valve malfunction of the Krupin eye valve with disk. J Glaucoma. Jun. 1997;6(3):152-6.
Chiou et al. “Ultrasound biomicroscopy of eyes undergoing deep sclerectomy with collagen implant” Br J Ophthalmol 80 (1996), pp. 541-544.
Chylack LT, Bellows AR. Molecular sieving in suprachoroidal fluid formation in man. Invest Ophthalmol Vis Sci 17: 420, 1978.
Collaborative Normal-Tension Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-97.
Demailly et al. “Non-penetrating deep sclerectomy (NPDS) with or without collagen device (CD) in primary open-angle glaucoma: middle-term retrospective study” International Ophthalmology 20: 131-140, 1997.
Draeger “Chirurgische Maβnahmen bei kongenitalem Glaukom” (Surgical Interventions in Congenital Glaucoma) Klin Monatsbl Augenheilkd 1993; 202(5): 425-427 [Article in German with English summary included].
Ellis, RA “A Reduction of Intraocular Pressure Using Plastics in Surgery” Am J Ophth. 50; 1960, 733-742.
Fanous MM, Cohn RA. Propionibacterium endophthalmitis following Molteno tube repositioning. J Glaucoma. Aug. 1997;6(4):201-2.
Gills, “Cyclodialysis Implants in Human Eyes” Am J Ophth 61:1966,841-846.
Goldberg “Management of Uncontrolled Glaucoma With the Molteno System” Australian and New Zealand Journal of Ophthalmology 1987; 15: 97-107.
Gordon MO, Kass. MA, for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study. Design and baseline description of the participants. Arch Ophthalmol 1999:573-83.
Grant, W.M. , MD, Further Studies on Facility of Flow Through the Trabecular Meshwork, A.M.A. Archives of Ophthalmololgy, Oct. 1958, vol. 60, pp. 523-533.
Harper SL, Foster CS. Intraocular lens explantation in uveitis. Int Ophthalmol Clin. 2000 Winter; 40(1):107-16.
Harrington “Cataract and Glaucoma. Management of the coexistent conditions and a description of a new operation combining lens extraction with reverse cyclodialysis.” Am J Ophthalmol. May 1996;61(5 Pt 2):1134-40.
Heijl A, Leske MC, Bengtsson B, et al for the Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression. Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79.
Hoskins, et al., “Aqueous Humor Outflow”, Becker-Shaffer's Diagnosis and Therapy of the Glaucomas, 6th Edition, Chapter 4, pp. 41-66, 1989.
Javitt JC, Chiang YP. Preparing for managed competition. Utilization of ambulatory eye care visits to ophthalmologists. Arch Ophthalmol 1993;111:1034-5.
Jay JL, Allan D. The benefit of early trabeculectomy versus conventional management in primary open-angle glaucoma relative to severity of disease. Eye 1989; 3:528-35.
Kass MA, Heuer DK, Higginbotham EJ, et al for the Ocular Hypertension Treatment Study Group. The Ocular HypertensionTreatment Study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13.
Klemm et al. “Die Ultraschallbiomikroskopie als Kriterium der Funktionsprüfung des suprachorioidalen Spaltes nach kammerwinkelchirurgischen Eingriffen (Ultrasound Biomicroscopic Imaging for Assessment of the Suprachoroidal Cleft after Angle Surgery)” Klinische Monatsblätter für Augenheilkunde 1997; 210: 74-77 [Article in German with English summary included].
Krejcí L. “Microdrainage of anterior chamber of eye glaucoma operation using hydron capillary drain.” Acta Univ Carol Med Monogr. 1974;(61):1-90.
Kupfer “Studies on intraocular pressure. I. A technique for polyethylene tube implantation into the anterior chamber of the rabbit.” Arch Ophthalmol. Apr. 1961;65:565-70.
La Rocca “Gonioplasty in Glaucoma*A Preliminary Report” Br J Ophth 46:1962, 404-415.
Law et al., “Retinal Complications After Aqueous Shunt Surgical Procedures for Glaucoma” Arch Ophthal.; Dec. 1996; vol. 114:1473-1480.
Lee KY. Trabeculo-suprachoroidal shunt for treating recalcitrant and secondary glaucoma. Presented at the American Academy of Ophthalmology Annual Meeting, Anaheim, CA, 1991.
Leske MC, Heijl A, Hussein M, et al for the Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment. The Early Manifest Glaucoma Trial. Arch Ophthalmol Jan. 2003;121:48-56.
Lichter PR, Musch DC, Gillespie BW, et al and the CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53.
Marx et al., “Use of the Ganciclovir Implant in the Treatment of Recurrent Cytomegalovirus Retinitis” Arch Ophthal.; Jul. 1996; vol. 114:815-820.
McPherson “Combined Trabeculotomy and Cataract Extraction as a Single Operation*” TR. AM. Ophth. Soc., vol. LXXIV, 1976; 251-260.
Migdal C, Gregory W, Hitchings R. Long term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology 1994;101:1651-7.
Miglior S, Zeyen T, Pfeiffer N, et al for the European Glaucoma Prevention Study Group. The European Glaucoma Prevention Study design and baseline description of the participants. Ophthalmology 2002;109:1612-21.
Miki, MD et al., “Intraocular Cannula for Continuous, Chronic Drug Delivery- Histopathic Observations and Function” Arch Ophthal.; May 1985; vol. 103:712-717.
Molteno et al. “Long tube implants in the management of glaucoma” South African Medical Journal, Jun. 26, 1976;50(27):1062-6.
Molteno et al. “The Vicryl tie technique for inserting a draining implant in the treatment of secondary glaucoma.” Australian and New Zealand Journal of Ophthalmology 1986; 14: 343-354.
Moses RA “Detachment of ciliary body-anatomical and physical considerations” Investigative Ophthalmology & Visual Science, Assoc. For Research in Vision and Ophthalmology, US, vol. 4, No. 5, Oct. 1, 1965.
Nguyen et al., “Complications of Baerveldt Glaucoma Drainage Implants” Arch Ophthal.; May 1998; vol. 116:571-575.
O'Brien et al. “Cyclodialysis” Arch Ophthal. 1949;42(5):606-619.
Olsen, Timothy W., et al., Cannulation of the Suprachoroidal Space: A Novel Drug Delivery Methodology to the Posterior Segment, American Journal of Ophthalmology, vol. 142, No. 5, Nov. 2006, pp. 777-787.e2.
Portney GL, “Silicone elastomer implantation cyclodialysis.” Arch Ophthalmol 1973; 89: 10-12.
Pruett et al., “The Fishmouth Phenomenon-II. Wedge Scleral Buckling” Arch Ophthal.; Oct. 1977; vol. 95:1782-1787.
Qadeer “Acrylic Gonio-Subconjunctival Plates in Glaucoma Surgery” Br J Ophthalmol. Jun. 1954; 38(6): 353-356.
Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997; 38:83-91.
Richards et al. “Artificial Drainage Tubes for Glaucoma” Am J Ophth 60:1965,405-408.
Ritch, et al., “Uveoscleral Outflow”, The Glaucomas. St. Louis: Mosby, 1996; pp. 337-343.
Rohen, Johannes W., Anatomy of the Aqueous Outflow Channels, Glaucoma, vol. 1, Chapter 14, pp. 277-296, Edited by J.E. Cairns, Grune & Stratton, Harcourt Brace Jovanovich Publishers, 1986.
Rowan, Patrick J., MD, Combined Cyclodialysis and Cataract Surgery, Ophthalmic Surgery and Lasers, Dec. 1998, vol. 29, No. 12, pp. 962-968 (9 pages).
Sampimon “A New Approach to Filtering Glaucoma Surgery” Ophthalmologica (Basel) 151: 1966, 637-644.
Schappert S. Office visits for glaucoma: United States, 1991-92. Advance data from vital and health statistics. vol. 262. Hyattsville, MD: National Center for Health Statistics, 1995.
Shaffer RN, Weiss DI. Concerning cyclodialysis and hypotony. Arch Ophthalmol 68: 25, 1962.
Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med 1991;325:1412-7.
Sourdille et al. “Reticulated hyaluronic acid implant in non-perforating trabecular surgery.” J Cataract Refract Surg 25: 332-339. (1999).
Suguro K, Toris CB, Pederson JE. Uveoscleral outflow following cyclodialysis in the monkey eye using a fluorescent tracer. Invest Ophthalmol Vis Sci 1985: 26, 810.
The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130:429-40.
The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. The Glaucoma Laser Trial Research Group. Ophthalmology 1990;97:1403-13.
The Glaucoma Laser Trial (GLT) and Glaucoma Laser Trial Follow-up Study: 7. Results. Am J Ophthahnol 1995;120:718-31.
Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA 1991;266:369-74.
Toris et al. “Effect of intraocular pressure on uveoscleral outflow following cyclodialysis in the monkey eye.” Investigative Ophthalmology & Visual Science. 26 (1985) 1745-1749.
Toris CB. Extravascular albumin concentration of the uvea. Invest Ophthalmol Vis Sci 1990; 31:43.
Troncoso, Manuel U., Tantalum implants for inducing hypotny, Am Journal of Ophthalmology, vol. 32(4):499-508 (1949).
Veen et al. “The gonioseton, a surgical treatment for chronic glaucoma” Documenta Ophthalmologica, vol. 75, Nos. 3-4, 365-375. (1990).
Wagner, Justin A., et al., Characterization of Uveoscleral Outflow in Enucleated Porcine Eyes Perfused under Constant Pressure, Invest Ophthalmol Vis Sci., Published in edited form in Sep. 2004, vol. 45, Issue 9, pp. 3203-3206.
Related Publications (1)
Number Date Country
20100152641 A1 Jun 2010 US
Continuations (2)
Number Date Country
Parent 11509327 Aug 2006 US
Child 12711201 US
Parent 10429336 May 2003 US
Child 11509327 US